Biomerica Inc Stock Price, News & Analysis

Biomerica (NASDAQ: BMRA) has received approval from the UAE Ministry of Health and Prevention for its Fortel® Kidney Disease Test, enabling commercial expansion in the UAE market. The 10-minute urine test detects early signs of kidney damage by measuring microalbumin levels.

The approval addresses a significant healthcare need in the UAE, where over 12% of adults have diabetes and 29-35% have hypertension - major risk factors for chronic kidney disease (CKD). The test targets high-risk individuals, including those with diabetes, hypertension, obesity, and people over 65.

CKD is globally underrecognized, with more than 80% of at-risk patients undiagnosed. By 2040, it's projected to be the 5th highest cause of years of life lost globally. Early detection enables timely intervention to prevent progression to end-stage renal disease, potentially reducing healthcare costs and improving patient outcomes.

Biomerica (NASDAQ: BMRA) has announced a 1-for-8 reverse stock split effective April 21, 2025, aimed at regaining compliance with Nasdaq's minimum bid price requirement. The split will automatically convert every 8 pre-split shares into one new share, reducing outstanding shares from approximately 20.37 million to 2.55 million.

The company's common stock will continue trading on The Nasdaq Capital Market under the symbol 'BMRA' with a new CUSIP number (09061H406). The split was authorized at Biomerica's 2024 Annual Meeting on December 13, 2024. Fractional shares will be rounded up to the next whole share.

Proportionate adjustments will be made to equity awards, option exercise prices, and shares available under stock incentive plans. The par value remains unchanged. Stockholders holding shares electronically will receive transaction notices, while those holding through brokers will have positions automatically adjusted.

Biomerica (NASDAQ: BMRA) reported Q3 fiscal 2025 financial results with 10% year-over-year revenue growth to $1.10 million. The company achieved significant improvements in financial metrics, including a gross margin increase from -15% to +2% and a 37% reduction in operating expenses to $1.20 million.

Key developments include UAE regulatory approval for the Fortel® PSA Screening Test, publication of positive inFoods® IBS clinical trial results in Gastroenterology journal, and CE-IVDR certification for new food intolerance products targeting Ulcerative Colitis.

The company reached its cost savings target early, delivering $1.1 million in savings (16% of annual operating expenses) within the first nine months. Cash burn improved by over 55% to $800,000 quarterly, with cash and equivalents at $3.06 million as of February 28, 2025.

Biomerica (NASDAQ: BMRA) has secured IVDR certification in the European Union for its food intolerance diagnostic products targeting Crohn's Disease and Ulcerative Colitis. The certification validates compliance with the EU's new In Vitro Diagnostic Medical Devices Regulation (IVDR – 2017/746), demonstrating the products' safety, quality, and performance standards.

The company's proprietary technology helps identify specific foods that may trigger inflammation in patients with these inflammatory bowel diseases (IBD). This certification positions Biomerica to expand its presence in the European market and potentially facilitate access to other international markets that recognize EU IVDR certification.

The company is currently finalizing materials for product launch in the near future, focusing on providing non-invasive and personalized solutions for IBD management.

Biomerica (NASDAQ: BMRA) has published clinical trial results for its inFoods® IBS test in Gastroenterology journal. The test identifies specific foods triggering elevated IgG antibody responses in IBS patients. A randomized, double-blind trial with 238 patients across eight U.S. academic centers showed significant results:

The treatment group following personalized elimination diets showed 59.6% success rate in pain reduction compared to 42.2% in the control group. Results were particularly strong for IBS-C patients (67.1% vs 35.8%) and IBS-M patients (66% vs 29.5%).

The test enables patients to eliminate only 2-4 trigger foods on average, offering a more targeted approach compared to traditional restrictive diets. This advancement is particularly significant for IBS-M patients, for whom no FDA-approved medications currently exist.

Biomerica (NASDAQ: BMRA) has received approval from the United Arab Emirates Ministry of Health and Prevention for its Fortel® PSA Screening Test, a 10-minute diagnostic tool for detecting prostate cancer markers through finger-prick blood samples. The test has demonstrated impressive clinical performance with 100% sensitivity, 95% specificity, and 97.5% accuracy in studies.

This approval marks a strategic expansion in the Middle East market, where Biomerica already has success with its EZ Detect Colon Disease Test. The Fortel® PSA test aims to address the growing concern of prostate cancer, which is the second most common cancer in men globally with 1.4 million new cases and 375,000 deaths reported in 2020.

The company is working with regional distributors to make early cancer detection more accessible, building on their previous achievement of securing government insurance reimbursement in Dubai for their colon screening test.

Biomerica (NASDAQ: BMRA) reported Q2 fiscal 2025 results showing a 5% year-over-year revenue growth to $1.64 million. The company achieved significant improvements in financial metrics, including gross margin expansion from 21% to 27% and a 26% reduction in operating expenses to $1.43 million.

Key developments include the direct-to-consumer launch of inFoods® IBS Test and securing three patents for inFoods® technology covering GERD, Crohn's Disease, and Ulcerative Colitis in multiple European countries. The company's cost-saving initiatives delivered approximately $670,000 in savings, targeting annual reductions of $1.0-1.4 million.

Operating losses decreased by 39% to $990,000, while net losses reduced by 37% to $950,000. Cash position stood at $2.37 million at quarter-end, down from $2.82 million in Q1.

Biomerica (NASDAQ: BMRA) has secured three key patent allowances in European markets for its inFoods® Technology, targeting GERD, Crohn's Disease, and Ulcerative Colitis. The patents cover major European markets including Germany, UK, France, Italy, Spain, and over 30 other EPO nations. These markets represent significant opportunities: GERD ($4B+ annually), Crohn's Disease ($2.5B+ annually), and Ulcerative Colitis (projected $1.9B by 2028). The inFoods® Technology platform identifies specific foods triggering symptoms in patients, enabling personalized dietary plans as alternatives to traditional medications, particularly addressing concerns over PPI side effects in GERD treatment.

Biomerica (BMRA) has received a 180-day extension from Nasdaq to meet the minimum $1.00 per share bid price requirement for continued listing. The company now has until May 5, 2025, to regain compliance by maintaining a closing bid price of $1.00 or higher for at least ten consecutive business days. The extension was granted as Biomerica meets all other Nasdaq Capital Market listing requirements, including minimum market value of publicly held shares. The company has expressed its commitment to maintaining its Nasdaq listing and is actively working to meet the bid price requirement.